

DAFTAR PUSTAKA

1. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anemia. *Lancet*. 2016;387.
2. Kassebaum NJ1, Jasrasaria R, Naghavi M. A systematic analysis of global anemia burden from 1990 to 2010. *Blood*. 2014;123(5):615—24.
3. Bowling CB, Inker LA, Gutierrez OM, Allman RM, Warnock DG. Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications. *Clin J Am Soc Nephrol*. 2011;6:2822.
4. Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004. *Clin J Am Soc Nephrol*. 2009;4:57—61.
5. Stancu S, Stanciu A, Zugravu A. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. *Am J Kidney Dis*. 2010;55:639—647.
6. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. *J Nephrol*. 2006;19:161—167.
7. Limori S, Naito S, Noda Y. Anemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study. *Nephrology (Carlton)*. 2015;20:601—608.
8. Felix E, Linda W, Emma S. Gambaran anemia defisiensi besi pada PGK stadium 5 yang menjalani hemodialisis di RSUP Prof. Dr. R. D. Kandou Manado. *Jurn e-Cl*. 2016;4:146—51.
9. van Nooten FE, Green J, Brown R, Finkelstein FO, Wish J. Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: review of the literature. *J Med Econ*. 2010;13:241—256.
10. Finkelstein FO, Story K, Firanek C, Mendelssohn D, Barre P, Takano T. Health related quality of life and hemoglobin levels in chronic kidney disease patients. *Clin J Am Soc Nephrol*. 2009;4(1):33—8.

11. KDOQI; National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. *Am J Kidney Dis.* 2012;47[Suppl 3]:S11—S145.
12. Bahrainwala J, Berns JS. Diagnosis of iron-deficiency anemia in chronic kidney disease. *Semin Nephrol* 2016;36:94—98.
13. Jay BW. Assessing iron status: beyond serum ferritin and transferrin saturation. *Clin J Am Soc Nephrol.* 2006;1:S4—S8.
14. R'Zik S, Beguin Y. Serum soluble transferrin receptor concentration an accurate estimate of the mass of tissue receptors. *Exp Hematol.* 2001;29:677—85.
15. Ayesha M, Aisha H, Iram A, Muhammad A, Shahida M, Shabbir H. Soluble serum transferrin receptor levels in hemodialysis patients. *Annals.* 2016;22:290—5.
16. Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent and assessment of iron deficient state. *Clin Lab Haem.* 2006;28:303—308.
17. Canals C, Remacha AF, Sarda MP. Clinical utility of the new sysmex xe 2100 parameter-reticulocyte hemoglobin equivalent in the diagnosis of anemia. *Hematology.* 2005;90.
18. Chuang CL, Liu RS, Wei YH, Huang TP, Tarng DC. Early prediction of response to intravenous iron supplementation by reticulocyte hemoglobin content and high-fluorescence reticulocyte count in hemodialysis patients. *Nephrol Dial Transplant.* 2003;18:370—7.
19. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients. *Kidney Int.* 2001;60:2406—11.
20. Mast A, Blinder M, Lu Q, Flax S, Dietzen D. Clinical utility of the reticulocyte hemoglobin equivalent in the diagnosis of iron deficiency. *Blood.* 2002;99.
21. Deng L, Teng H, Li Y. Clinical utility of reticulocyte hemoglobin equivalent for the diagnosis of iron deficiency anemia. *Zhongguo Dang Dai.* 2011;13.

22. Locatelli F, Aljama P, Barany P. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. *Nephrol Dial Transplant*. 2004;19(suppl 2):1—47.
23. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. *J Am Soc Nephrol*. 2002;13:504—10.
24. El-Achkar TM, Ohmit SE, McCullough PA. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: the Kidney Early Evaluation Program. *Kidney Int*. 2005;67:1483—1488.
25. Jodie L, Babitt YL, Herbert YL. Mechanisms of anemia in chronic kidney disease. *J Am Soc Nephrol*. 2012; 23: 1631—1634.
26. McClellan W, Aronoff SL, Bolton WK. The prevalence of anemia in patients with chronic kidney disease. *Curr Med Res Opin*. 2004;20:1501.
27. Macdougall IC, Cooper AC. Erythropoietin resistance: role of inflammation and pro-inflammatory cytokines. *Nephrol Dial Transplant*. 2002;17(suppl 11):39—43.
28. Ganz T. Hpcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. *Blood*. 2003;102:783—88.
29. Ganz T. Systemic iron homeostasis. *Physiol Rev*. 2013; 93: 1721—41.
30. Donnelly S. Why is erythropoietin made in the kidney? The kidney functions as a critmeter. *Am J Kidney Dis*. 2001;38:415—25.
31. Gulec, S, Anderson GJ, Collins JF. Mechanistic and regulatory aspects of intestinal iron absorption. *Am J Physiol Gastrointest Liver Physiol*. 2014;307:G397—G409.
32. Gkouvatso K, Papanikolaou G, Pantopoulos K. Regulation of iron transport and the role of transferrin. *Biochim Biophys Acta*. 2012;1820:188—202.
33. Palis J. Primitive and definitive erythropoiesis in mammals. *Front Physiol*. 2014;5:3.
34. Harms K, Kaiser T. Beyond soluble transferrin receptor: old challenges and new horizons. *Best Pract Res Clin Endocrinol Metab*. 2015;29:799.

35. Nemeth E, Tuttle MS, Powelson J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing internalization. *Science*. 2004;306:2090—93.
36. Wang CY, Babitt JL. Hepcidin regulation in the anemia of inflammation. *Curr Opin Hematol*. 2016;23:189—197.
37. Drakesmith H, Nemeth E, Ganz T. Ironing out Ferroportin. *Cell Metab*. 2015;22:777—87.
38. Nai A, Lidonnici MR, Rausa M. The second transferrin receptor regulates red blood cell production in mice. *Blood*. 2015;125:1170—79.
39. Saul N. Anemia in chronic kidney disease: causes, diagnosis, treatment. *Cleveland Clin J Med*. 2006;73:289—97.
40. Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med*. 2005;352:1011—23
41. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. *Lancet*. 2016;387:907—16.
42. Marijn MS, Reinhart S, Joris RD. Biological and clinical aspects of soluble transferrin receptor. *Crit Rev Clin Lab Sci*. 2011; 47: 213—228.
43. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. *Clin Chim Acta*. 2003;329:9—22.
44. Kohgo Y, Torimoto Y, Kato J. Transferrin receptor in tissue and serum: updated clinical significance of soluble receptor. *Int J Hematol*. 2002;76:213—28.
45. Choi JW, Im MW, Pai SH. Serum transferrin receptor concentrations during normal pregnancy. *Clin Chem* 2000;46:725—27.
46. Punnonen K, Suominen P, Kuusinen A, Kuiper-Kramer E. Clinical use of soluble transferrin receptor. *Clinical Chemistry & Laboratory Medicine*. 2000;38(4):377.
47. Suominen P, Mottonen T, Rajamaki A, Irjala K. Single values of serum transferrin receptor and transferrin receptor ferritin index can be used to detect true and functional iron deficiency anemia. *Arthritis Rheum* 2000;43:1016—20.

48. Wollmann M, Branca M, Vanessa S, Rafael WF, Guilherme OR. Reticulocyte maturity indices in iron deficiency anemia. Elsevier. 2014;36:25—28.
49. Urrechaga E, Borque L, Escanero JF. Analysis of reticulocyte parameters on the sysmex we 5000 and lh 750 analyzers in the diagnosis of inefficient erythropoiesis. *Int J Lab Pathol*. 2011;33:37—44.
50. Wirawan R, Tedja AT, Henrika F, Lydia A. Concordance between reticulocyte hemoglobin equivalent and reticulocyte hemoglobin content in CKD patients undergoing hemodialysis. *Acta Medica Indonesiana*. 2017;49:34—40.
51. Semmelrock M, Raggam R, Amrein K, Avian A, Schallmoser K, Lanzer G. Reticulocyte hemoglobin content allows early and reliable detection of functional iron deficiency in blood donors. *Clinica Chimica Acta*. 2012;413:678—82.
52. Frank S, Linssen J, Messinger M, Thomas L. Potential utility of Ret-Y in diagnosis of iron-restricted erythropoiesis. *Clin Chem*. 2004;50:1240—2.
53. Aoun M, Karam R, Sleilaty G, Antoun L, Ammar W. Iron deficiency across chronic kidney disease stages : is there a reverse gender pattern? *Plos One*. 2018;12:1—12.
54. Alagoz S, Dincer MT, Eren N, Bakis A, Pekpak M, Trabulus S, et al. Prevalence of anemia in predialysis chronic kidney disease : Is the study centre a significant factor? *Plos One*. 2020;15:4.
55. Awidi M, Bawaneh H, Zureigat H, AlHusban M, Awidi A. Contributing factors to iron deficiency anemia in women in Jordan : A single-center cross-sectional study. *Plos One*. 2018;13:1—10.
56. Friedman AJ, Chen Z, Ford P, Johnson CA, Lopez AM, Shander A et al. Iron deficiency anemia in women across the life span. *Journal of Women's Health*. 2012;21:1282—9.

57. Wong M, Charlotte T, Yun L, Rachel P, Roberto P, Antonio A, et al. Anemia and iron deficiency among chronic kidney disease stage 3-5ND patients in the chronic kidney disease outcomes and practice patterns study : often unmeasured, variably treated. *Clinical Kidney Journal*. 2020;13:613—24.
58. Franceschi LD, Iolascon A, Taher A, Cappellini MD. Clinical management of iron deficiency anemia in adults : Systemic review on advances in diagnosis and treatment. *Eur J Intern Med*. 2017; 1—8.
59. Alam F, Fatima SS, Noor S, Bilal A, Rehman R. Stages of chronic kidney disease and soluble transferrin receptor (sTfR), ferritin, ratio. *J Pak Med Assoc*. 2017;67:848—51.
60. Zhu Y, Liu X, Li N, Cui L, Zhang X, Liu X, et al. Association between iron status and risk of chronic kidney disease in chinese adult. *Frontiers in Medicine*. 2020;6:1—9.
61. Venkatesan M, Saxena S, Kumar A. Evaluation of iron status in patients of chronic kidney disease : a study to assess the best indicators including serum transferrin receptor assay. *Indian J Nephrol*. 2019;29:248—53.
62. Lukas D, Hernaningsih Y, Triantanoe A. Diagnostic value of reticulocyte hemoglobin and soluble transferrin receptor in determining the iron status of chronic kidney disease with hemodialysis patients. *Asian J Pharm Clin Res*. 2019;12:210—14.
63. Latif A, Alam MR, Khanam A, Hoque F, Rahim MA, Islam RN, et al. Role of serum transferrin receptor in diagnosing and differentiating iron deficiency anemia from anemia of chronic disease in patients with chronic kidney disease. *Birdem Med J*. 2017;7:132—7.
64. Lukaszyk E, Lukaszyk M, Zorawka E, Tobolczyk J, Lukaszyk A, Malyszko J. Iron status and inflammation in early stages of chronic kidney disease. *Kidney Blood Press Res*. 2015;40:366—73.
65. Dalimunthe NN, Lubis AR. Usefulness of reticulocyte hemoglobin equivalent in management of regular hemodialysis patients with iron deficiency anemia. *Rom J Intern Med*. 2016;54:31—6.

66. Poffenroth C, Mabbett C, Kendrick C. The reticulocyte hemoglobin equivalent (Ret-He) and laboratory screening for iron deficiency. *NZ J Med Lab Sci.* 2017;71:120—23.
67. Rachmiwatie A, Noormartany, Gondodiputro R, Prihatni D. Reticulocyte hemoglobin level of absolute iron deficiency anemia and non absolute iron deficiency anemia in end state renal disease undergoing maintenance hemodialysis. *Indonesia Journal of Clinical Pathology and Medical Laboratory.* 2014;21:32—9.
68. Wirawan R, Arlinda T. Peran parameter retikulosit tambahan pada tatalaksana penyakit ginjal kronis. *Semiloka Mutu. Badan Khusus Pkel Patklin.* 2017.
69. Sany D, Shahawi YE, Taha J. Diagnosis of iron deficiency in hemodialysis patients : Usefulness of measuring reticulocyte hemoglobin equivalent. *Saudi J Kidney Dis Transpl.* 2020;31:1263—72.

